Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Demyelination17.16.02.0010.000070%Not Available
Dental caries07.09.01.0010.000035%
Depressed level of consciousness17.02.04.0020.000245%
Dermal cyst23.10.02.001; 16.26.02.0010.000070%Not Available
Dermatitis23.03.04.0020.000157%Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Dermatitis bullous23.03.01.0020.000105%
Dermatitis exfoliative23.03.07.001; 10.01.01.0040.000052%
Dermatomyositis10.04.04.027; 23.03.02.001; 15.05.01.0020.000105%Not Available
Diabetes insipidus14.05.07.003; 05.03.03.0040.000122%Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.001667%Not Available
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.000070%Not Available
Diabetic ketoacidosis14.07.03.001; 05.07.03.0010.000350%Not Available
Diarrhoea haemorrhagic24.07.02.004; 07.02.01.0020.000140%Not Available
Diffuse large B-cell lymphoma16.28.02.001; 01.15.02.0010.000210%Not Available
Diplegia17.01.04.015--Not Available
Diplopia17.17.01.005; 06.02.06.0020.000105%Not Available
Discomfort08.01.08.003--Not Available
Disorientation17.02.05.015; 19.13.01.0020.000157%Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.000594%
Diverticulum07.10.01.0010.000052%Not Available
Diverticulum intestinal07.10.01.0020.000052%Not Available
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.000105%Not Available
Drug ineffective08.06.01.0060.005460%Not Available
Drug interaction08.06.03.0010.002052%Not Available
Dry skin23.03.03.001--
Duodenal perforation07.04.02.0010.000035%
Duodenal ulcer07.04.02.0020.000245%
Duodenal ulcer haemorrhage24.07.02.020; 07.04.02.0040.000035%Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene